Our vision and mission
We aspire to translate science into survival
At BioNTech, we are dedicated to improving the health of people worldwide by harnessing the full potential of the human immune system to develop drugs for diseases with high or unmet medical needs. In pursuit of our vision, we are focused on oncology and medicines against a range of infectious diseases. We aim to create long-term value for people and society by pioneering the next generation of immunotherapies and vaccines. With our key capabilities in immunology, deep genomics, and artificial intelligence, we believe we are well-positioned to do so.
From discovery to delivery: Our fully integrated approach to medicine
As a global biotechnology company, our fully-integrated model encompasses scientific groundwork, translational drug discovery, clinical development, GMP manufacturing and commercialization. With our patient-centric treatment approaches we want to become a biotechnological leader in oncology and infectious diseases.
Our oncology strategy
Our primary focus is oncology, where we endeavor to address the full continuum of cancer from early to late disease stages. We approach the root causes of cancer treatment failure – cancer heterogeneity and interindividual variability – through innovative therapeutic modalities with the aim to expand treatment options for patients.
Our approach to infectious diseases
Infectious diseases rank among the leading causes of death globally and remain a significant area of BioNTech’s work. Our goal is to advance the development of innovative vaccines and therapeutics targeting viruses, bacteria and parasites for high medical need indications.
Strategic outlook
BioNTech's vision is to establish a multi-product company that helps patients with unmet and high medical needs. We are committed to advancing our strategy by focusing on medicines with disruptive potential and developing combination treatments based on novel drug candidates. Our dedication to innovation drives us to explore applications beyond oncology and infectious diseases, including autoimmune and neurodegenerative conditions.
Explore more
Our board members
Sites & subsidiaries
